Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/27022
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17775/20116 (88%)
造访人次 : 10231167      在线人数 : 457
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cnu.edu.tw/handle/310902800/27022


    標題: Serum Vascular Adhesion Protein-1 Predicts 10-Year Cardiovascular and Cancer Mortality in Individuals With Type 2 Diabetes
    作者: Li, Hung-Yuan
    Jiang, Yi-Der
    Chang, Tien-Jyun
    Wei, Jung-Nan
    Lin, Mao-Shin
    Lin, Cheng-Hsin
    Chiang, Fu-Tien
    Shih, Shyang-Rong
    Hung, Chi Sheng
    Hua, Cyue-Huei
    David, J.Smith
    Vanio, Jani
    Chuang, Lee-Ming
    貢獻者: 職業安全衛生系
    關鍵字: Sensitive Amine Oxidase
    Hepatocellular-Carcinoma
    Colorectal-Cancer
    Leukocyte Binding
    Tumor Endothelium
    P-Selectin
    Disease
    Risk
    Overexpression
    Adipocytes
    日期: 2011-03
    上傳時間: 2013-10-23 11:55:48 (UTC+8)
    出版者: Amer Diabetes Assoc
    摘要: OBJECTIVE Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 correlates positively with both acute hyperglycemia and diabetes. We conducted a cohort study to evaluate whether serum VAP-1 predicts 10-year survival in type 2 diabetic patients.

    RESEARCH DESIGN AND METHODS Between July 1996 and June 2003, we enrolled 661 type 2 diabetic subjects at National Taiwan University Hospital. Serum VAP-1 in the samples obtained at enrollment was measured by time-resolved immunofluorometric assay. The vital status of all subjects was ascertained by linking their data with computerized death certificates in Taiwan.

    RESULTS The medium follow-up period was 10.4 years. Subjects with serum VAP-1 in the highest tertile had a hazard ratio (HR) of 2.19 (95% CI 1.17–4.11) for all-cause mortality adjusted for age, sex, smoking, history of cardiovascular disease, obesity, hypertension, hemoglobin A1c, diabetes duration, total cholesterol, use of statins, abnormal ankle-brachial index, estimated glomerular filtration rate (eGFR), and proteinuria. The adjusted HRs for logarithmically transformed serum VAP-1 were 5.83 (95% CI 1.17–28.97) for cardiovascular mortality, 6.32 (95% CI 1.25–32.00) for mortality from cardiovascular and diabetic causes, and 17.24 (95% CI 4.57–65.07) for cancer mortality. There were four variables, including age, serum VAP-1, proteinuria, and eGFR, which could enhance mortality prediction significantly.

    CONCLUSIONS Serum VAP-1 can predict 10-year all-cause mortality, cardiovascular mortality, and cancer mortality independently in type 2 diabetic subjects. Serum VAP-1 is a novel biomarker that improves risk prediction over and above established risk factors
    關聯: Diabetes , 60(3), pp.993-999
    显示于类别:[職業安全衛生系(含防災所)] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML753检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈